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Abstract
In hepatitis C virus (HCV) infection, there is accumulating data suggesting the presence of cellular immune responses to HCV in exposed
but seemingly uninfected populations. Some studies have suggested cross-reactive antigens rather than prior HCV exposure as the main
reason for the immune responses. In this study we address this question by analyzing the immune response of chimpanzees that have been
sequentially exposed to increasing doses of HCV virions. The level of viremia, as well as the immune responses to HCV at different times
after virus inoculation, were examined. Our data indicate that HCV infective doses as low as 1–10 RNA () virions induce detectable
cellular immune responses in chimpanzees without consistently detectable viremia or persistent seroconversion. However, increasing the
infective doses of HCV to 100 RNA () virions overcame the low-inoculum-induced immune response and produced high-level viremia
followed by seroconversion.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Hepatitis C virus (HCV) is one of the major health
problems in the world. The prevalence of HCV in adult
populations of most developed countries is 1–2% but infec-
tion rates are much higher in high-risk groups and in most
developing countries. WHO estimates that 3% of the
world’s population has been infected with HCV and that
170 million persons are chronic carriers. About 20% of
those with chronic HCV infections develop cirrhosis and/or
hepatocellular carcinoma (HCC). The annual incidence of
HCC is 2–4% in HCV carriers who have been infected for
20–30 years (Alter et al., 1999; Seeff et al., 2001).
Infection of chimpanzees with HCV results in patterns of
infection closely resembling those in man. In general, the
course of infection in chimpanzees with HCV can be sum-
marized as follows: HCV-RNA is usually detected in serum
3–7 days after infection and is rapidly amplified to levels of
106 copies/ml. Mild ALT elevation may occur in weeks
2–3; however, the main peak of ALT elevation does not
usually occur until 5–10 weeks after infection. In our expe-
rience HCV RNA usually remains detectable in self-limited
infection for 9–39 weeks (X  18.6) (Abe et al., 1992). In
chronic infection, which occurs in 50–80% of humans, and
about 50% of chimpanzees, HCV RNA remains detectable
for life (Prince and Brotman, 1994). However, neither cir-
rhosis nor hepatocellular carcinoma has been reported as a
complication of HCV infection in chimpanzees.
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HCV antigen-specific IFN- secreting T cells have been
observed in the peripheral blood and the intrahepatic lym-
phocytes (IHLs) during HCV infection (Anthony et al.,
2001; Cooper et al., 1999; Lechner et al., 2000; Rice and
Walker, 1995; Schirren et al., 2000; Shata et al., 2002). A
multispecific strong CD8 response may control HCV rep-
lication to some extent, yet the cellular immune response
appears to be unable to clear the virus in most HCV infec-
tions (Hiroishi et al., 1997; Rehermann et al., 1996; Wong
et al., 1998). However, when the cellular responses from
humans and chimpanzees that clear HCV infection were
analyzed, it has been found that viral clearance was associ-
ated with an early and broad CTL response to multiple HCV
epitopes (Cooper et al., 1999; Nelson et al., 1997; Shata et
al., 2002). Moreover, it was shown that chimpanzees that
cleared HCV infection are partially resistant to challenge
with HCV (Bassett et al., 2001; Major et al., 2002). Simi-
larly, a strong and persistent T cell response was associated
with viral clearance in patients acutely infected with HCV,
and in HCV-seronegative humans with exposure to HCV
(Bronowicki et al., 1997; Koziel et al., 1997; Lechner et al.,
2000; Takaki et al., 2000).
In HIV infection, high-risk individuals with repeated
exposure to HIV, but without disease, seroconversion, or
viremia, have been shown to have strong cellular immune
responses against HIV. It has been suggested that the strong
cellular immune responses in these individuals protected
them from detectable HIV infection, or modified the course
of disease following a fully infectious challenge. In the
present study we examined the threshold of the infective
doses of HCV that could induce cellular immune responses
to HCV without detectable viremia, or seroconversion. We
also examine the impact of low-inoculum-induced immune
responses on establishment of persistent versus resolved
infection following higher dose challenge.
Results
Titration of the infective doses and induction of anti-HCV
humoral responses
To determine the infectious titer (CID50), plasma of the
chronically HCV-infected chimpanzee (chimpanzee 317),
taken 2–4 weeks after inoculation and before the appear-
ance of anti-HCV, was diluted to have approximately 1, 10,
and 100 RNA () virions/ml. Two virgin chimpanzees,
chimpanzee 251 and chimpanzee 325, were challenged with
progressively higher doses of RNA () virions as described
under Materials and methods. Sera, PBLs, and liver biopsies
were collected from these chimpanzees at different time
points after challenge and were subjected to immunological
and virological studies. As shown in Fig. 1A and B, HCV
RNA could not be detected by real-time PCR in the sera of
either chimpanzee except after challenge with 100 RNA
(). However, transient, very low level viremia in chim-
panzee 325 was detected three independent times when
tested by a transcription-mediated amplification (TMA) as-
say for HCV, which has a sensitivity of 14 copies/ml (50%
detection limit) (Fig. 1B). Viral replication was detected by
quantitative PCR after challenge with 100 RNA () virions,
but was self-limited in chimpanzee 251, lasting about 12
weeks. In contrast, in chimpanzee 325, viremia initially
peaked, then dropped, then rebounded again, and subse-
quently persisted for more than 50 weeks at a low set point
(105 copies/ml). After challenge with 10 RNA () viri-
ons, despite the absence of detectable viremia, borderline
short-lived increases in the level of anti-HCV antibodies
were observed in both chimpanzees (Fig. 1A and B). The
anti-HCV levels were boosted dramatically after challenge
with 100 RNA () virions. In chimpanzee 251, the level of
anti-HCV dropped after 30 weeks to borderline and re-
mained low thereafter. By comparison, the level of anti-
HCV in chimpanzee 325 dropped initially during the first 12
weeks with decrease in viral load but rebounded to a high
level after reappearance of viremia and persisted thereafter.
The levels of liver enzymes (AST and ALT) were not
significantly changed after challenging with different doses
of HCV (data not shown).
HCV-specific cellular immune responses in peripheral
blood
Cryopreserved peripheral blood lymphocytes (PBLs)
from chimpanzees 251 and 325, at different time points after
infection, were examined using IFN- ELISPOT assays. To
measure the presence of HCV-specific activated effector T
cells, crypreserved PBLs were thawed and used directly
without expansion in the IFN- ELISPOT assay (ex vivo
ELISPOT). Cells were stimulated for 18 h with autologous
target cells infected with HCV (NS3, C-through NS3, or
NS3 through NS5)-recombinant vaccinia virus. As shown in
Fig. 2A and B, an increase in the number of IFN--secreting
cells (ISCs) from chimpanzees 251 and 325 was seen even
after challenge with an estimated single RNA () virion
(285 and 195 ISCs/106 cells, respectively). The ISC number
increased after challenge with a dose of 10, but not signif-
icantly after challenge with 100 RNA () molecules. We
observed that the responses to NS3-vaccinia constructs were
not always in agreement with the responses to C-NS3 or
NS3-NS5-vaccinia constructs, although all the constructs
contain the NS3 region. The reason for this discrepancy is
not known, but it may reflect differences in the processing
of dominant NS3 epitopes among these constructs, as well
as changes in the dominant epitopes due to mutation.
To measure the presence of HCV-specific memory T
cells, crypreserved PBLs from chimpanzees 251 and 325
were thawed and expanded in vitro with autologous target
cells infected with ALVAC-HCV (core through NS3) for 6
days. Expanded cells were assessed for HCV specificity
using IFN- ELISPOT assay (in vitro expanded ELISPOT).
As shown in Fig. 3A and B, memory HCV-specific T cells
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Fig. 1. Viral load and anti-HCV level after challenge with different doses of HCV. Sera from chimpanzees 251 (A) and chimpanzee 325 (B) were tested for
anti-HCV (filled triangle) and viral load (filled circle) at different time points after challenge with HCV, using quantitative ELISA and PCR, respectively.
The lower detection limit (LDL) of quantitative PCR is 250 copies/ml, and for qualitative TMA assay is 14 copies/ml at 50% detection limit. The lower
detection limit of anti-HCV antibodies is 0.2 units/ml.
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from chimpanzees 251 and 325 were detected even after
challenge with 1 RNA () molecule (2125 and 1525 ISCs/
106 cells, respectively). The pool of memory T cells in both
chimpanzees did not increase significantly after challenge
with higher doses (10 and 100 RNA), which is in agreement
with another article (Blattman et al., 2000). To find if there
Fig. 3. Expanded ELISPOT for chimpanzees 251 and 325 after infection with different doses. Expanded PBLs from chimpanzee 251 (A) and chimpanzee
325 (B) were tested for anti-HCV cellular response using IFN- ELISPOT assay as described under Materials and methods. Briefly autologous PBLs cells
(at time 0) were infected for 1 h with recombinant HCV-C-NS3-Alvac (filled column) at an m.o.i. of 10:1 and used as stimulator cells. Autologous PBLs
from different time points after challenge were incubated with the stimulator cells for 1 week at 37°C and 5% CO2. On day 7, IFN- ELISPOT assay was
done as described in Fig. 2. The numbers of HCV-specific ISCs/106 cells were plotted after subtracting the background (parental vaccinia virus alone). The
cutoff value of ISCs (horizontal line) was calculated as described under Materials and methods as approximately 870.3 ISCs/106 cells.
Fig. 2. Direct ex vivo IFN- ELISPOT for chimpanzees 251 and 325 after infection with different doses. PBLs from chimpanzee 251 (A) and chimpanzee
325 (B) were tested for anti-HCV cellular response using IFN- ELISPOT assay as described under Materials and methods. Cells from time 0 (before
challenge) were infected with recombinant HCV-C-NS3-vaccinia (filled column), HCV-NS3-NS5 (unfilled column), or HCV-NS3 (hatched column) at an
m.o.i. of 10:1 and used as stimulator cells. PBLs from different time points after challenge were incubated with the stimulator cells, and the number of
IFN--secreting cells (ISCs) was measured 18 h after in vitro stimulation. IFN- ELISPOT was done at all time points indicated in the graph. Sera from
chimpanzees 251 and 325 were tested for viral load (line) using quantitative PCR as described in Fig. 1. The data represent average of two experiments. The
cutoff value of ISCs (horizontal line) was calculated as described under Materials and methods as approximately 185.5 ISCs/106. The average numbers of
direct ex vivo ISCs in the presence of parent vaccinia were 78  54 ISCs/106 cells.
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is a qualitative difference between memory T cells in chim-
panzees 251 and 325, the levels of IL-4 (data not shown)
and TNF- were measured in the supernatant of the in vitro
expanded C-NS3 stimulated T cells. As shown in Fig. 4A
and B, the levels of TNF- in the supernatant of memory T
cells after challenge with 10 and 100 RNA () molecules
were two- to threefold higher in chimp 251 (287 and 366.5
pg/ml, respectively) in comparison to chimp 325 (118 and
146 pg/ml, respectively). However, the levels of IL-4 in the
supernatant of the stimulated cells from the two chimpan-
zees were below the detection level (data not shown).
Responses to Class 1 restricted epitopes of HCV-NS3
protein
To identify responses to class I restricted epitopes of
HCV-NS3 protein of genotype 1b, 312 (10-mer) overlap-
ping peptides for NS3 genotype 1b were synthesized with
two amino acid offsets. Due to the limiting number of cells
for the assay (2  105 cells/well are needed for each
peptide), the peptides were used as pools of 10 peptides (32
pools were used). The peptide pools contained individual
peptides at a concentration of 4 nM, corresponding to the
Fig. 4. TNF- secretion from expanded ELISPOT for chimpanzees 251 and 325 after infection with different doses. The levels of TNF- in the supernatant
expanded PBLs from chimpanzee 251 (A) and chimpanzee 325 (B) were measured as previously described. TNF- was expressed as pg/ml after subtracting
the background (TNF- secreted by vaccinia vector alone). The cutoff value was calculated as the level of TNF- in the presence of vaccinia vector  2
SD and was approximately 200 pg/ml.
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optimum concentration for peptides with moderate binding
affinity to class I (Wentworth et al., 1996). The pooled
peptides were added for 18 h to the PBMCs from chimpan-
zees 251 and 325 at different time points after challenge,
and the peptide-specific cells were evaluated using direct ex
vivo IFN- secreting cells ELISPOT assay. As shown in
Fig. 5, there were multiple borderline NS3-reacting ISCs for
chimpanzee 251 even before challenge with HCV (Fig. 5A).
This may reflect cross-reactive antigens. One to two months
postchallenge with one RNA () virion, the responses to
NS3-specific epitopes were boosted significantly to previ-
ous recognized regions (such as pools 25, 41, 49, 153, 161,
and 297) (Fig. 5B). Moreover, new regions of NS3 were
recognized (such as pools 105, 113, 209, 241, 249, and
305). Conversely, the response to some previously recog-
nized epitopes were decreased in other NS3 regions (such as
pools 57, 65, 145, 169, 185, and 265). However, 3 months
postchallenge with one RNA (), the NS3-specific re-
sponses dropped dramatically in all the regions (data not
shown). Rechallenging chimpanzee 251 with 10 RNA
() molecules restricted the response to limited, previ-
ously recognized NS3 regions (pools 161 and 185) (Fig.
5C). Rechallenging chimpanzee 251 with 100 RNA ()
molecules stimulated a broad spectrum of NS3-specific
ISCs (Fig. 5D). Some ISC responses were to previously
recognized regions (such as pools 49, 57, and 241). Other
ISC responses were to newly recognized NS3 regions
(such as pools 73, 81, 121, 193, 217, and 289). The
change in the breadth of HCV epitope recognition was
previously reported by other laboratories and may be
related to the high mutation rate of HCV (Erickson et al.,
2001; Wang et al., 2002). In chimpanzee 325, no preex-
isting cross-reactive NS3 epitopes were recognized be-
fore challenge (Fig. 6A) and only a borderline response
to a few epitopes could be detected 1–2 months postchal-
lenge (Fig. 6B). The responses were absent or weaker in
general than that of chimpanzees 251 at all time points
(Figs. 5 and 6).
Fig. 5. NS3-epitope mapping of effector cells from chimpanzees 251 after challenge with 1-100 RNA () virion molecules. PBLs from chimpanzee 251 were
tested for cellular response to pools of 10-mer NS3 overlapping peptides using IFN- ELISPOT assay as described under Materials and methods. PBLs at
time 0 (A), after challenge with an estimated one RNA () molecule (B), or after challenge with 10 (C), and 100 (D) RNA () molecules, were incubated
with pools of ten 10-mer overlapping peptides of NS3 (HCV genotype 1b) at a concentration of 4 nM for each peptide. The numbers of IFN--secreting cells
(ISCs) were measured 18 h after in vitro stimulation. The numbers of HCV-specific ISCs/106 cells were plotted after subtracting the background (media
alone). The cutoff value of ISCs (horizontal line) was calculated as described under Materials and methods and estimated to be approximately 217 ISCs/106.
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HCV-specific cellular immune response of intrahepatic
lymphocytes (IHLs)
To identify T cell response of IHLs after challenge
with different doses of HCV, IHLs were prepared as
described under Materials and methods, and the number
of HCV-specific cells was evaluated using direct ex vivo
IFN--secreting-cells ELISPOT assay. As shown in Fig.
7A, there were significant increases in the number of
HCV-specific IFN--secreting cells 1 month postchal-
lenge with 1 RNA () virion in chimpanzee 251. How-
ever, in chimpanzee 325, very weak HCV-specific IHL
responses were seen only after challenge with 10 RNA
() virions and persisted thereafter (Fig. 7B). It is clear
that both the IHL and the PBL responses in chimpanzee
251 are stronger than those seen in chimpanzees 325 even
after challenge with 100 RNA () molecules and the
appearance of viremia.
Proliferation responses to HCV proteins
To identify proliferation responses to HCV proteins after
challenge with different doses of HCV RNA, PBMCs from
chimpanzees 251 and 325 collected at different time points
before and after challenge with HCV were examined in T
cell proliferation assays using 3H-thymidine incorporation.
No significant T cell proliferation (stimulation index  3)
was seen at all time points in chimp 325. However, in chimp
251, blastogenesis was seen only at week 59 (8 weeks
postchallenge with 100 RNA () molecules); the stimula-
tion index was 3.32, which declined later (data not shown).
This low-level stimulation with HCV proteins was not re-
Fig. 6. NS3-epitope mapping of effector cells from chimpanzees 325 after challenge with 1-100 RNA () virion molecules. PBLs from chimpanzee
325 were tested for cellular response to pools of 10-mer NS3 overlapping peptides using IFN- ELISPOT assay as described under Materials and
methods. PBLs at time 0 (A), and after challenge with an estimated one RNA () molecule (B), or after challenge with 10 (C), and 100 (D) RNA
() molecules, were incubated with pools of ten 10-mer overlapping peptides of NS3 (HCV genotype 1b) at a concentration of 4 nM for each peptide.
The numbers of IFN--secreting cells (ISCs) were measured 18 h after in vitro stimulation. The numbers of HCV-specific ISCs/106 cells were plotted
after subtracting the background (media alone). The cutoff value of ISCs (horizontal line) was calculated as described under Materials and methods
and estimated to be approximately 217 ISCs/106.
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lated to the viability of the thawed cells, since the PHA
stimulation index was 50 at all time points.
Discussion
It has been shown that about 20–50% of HCV infections
in humans are self-limited. Although cellular immune re-
sponses clearly play a significant role in controlling viral
multiplication (Cooper et al., 1999; Nelson et al., 1997), the
mechanisms by which those individuals are able to clear the
virus remain controversial (Cerny and Chisari, 1994, 1999;
Farci et al., 1992; Lai et al., 1994b; Prince et al., 1992).
Likewise, some high-risk individuals, such as the household
contacts of HCV-infected patients (Brettler et al., 1992;
Meisel et al., 1995) or up to 20% of injection drug abusers
consistently exposed to the virus through needle sharing
(Thomas et al., 1995), do not develop apparent infection
despite repeated exposure to HCV. The reasons for the
resistance to infection are not clear, but development of
cellular immune responses to HCV has been reported in
some seronegative healthy individuals who were either sex-
ual partners of HCV-infected patients, or laboratory person-
nel with possible occupational exposure to the virus
(Bronowicki et al., 1997; Koziel et al., 1997; Scognamiglio
et al., 1999).
This study addressed the two following important issues
of HCV infection: (1) The threshold of viral exposure that
elicits immune responses without detectable viremia and (2)
the nature of protective immunity in HCV. The chimpanzee
is an excellent model for the study of HCV infection. Anal-
ogous to humans, about 50% of chimpanzees clear the virus.
Immune exposed uninfected chimpanzees have not been
previously investigated. However, it has been shown that
chimpanzees with self-limited HCV infection were rela-
tively resistant to rechallenge with HCV infection (Bassett
et al., 2001; Major et al., 2002; Nascimbeni et al., 2003). In
this study, we examined the threshold dose of HCV that was
able to elicit specific cellular immune responses. Two “vir-
gin” (not experimentally infected with HCV) chimpanzees
were injected with increasing doses of HCV at 6-month
intervals, while both corresponding immune responses and
viral load were monitored. Our data indicated that low-dose
exposure to 1 or 10 RNA () virions could induce HCV-
specific cellular immune responses without quantifiable per-
sistent viremia or seroconversion. The levels of induced
immune responses were significantly different between the
two chimpanzees. Chimpanzee 251, which was able to clear
the infection even after high-dose challenge, had early
stronger cellular responses in comparison to chimpanzee
325, which failed to clear the infection and subsequently
became chronically infected. Ex vivo IFN- ELISPOT as-
Fig. 7. Response of intrahepatic lymphocytes (IHLs) from chimpanzees 251 and 325 to HCV after challenge with different doses. IHLs prepared as described
under Materials and methods, from chimpanzee 251 (A) or chimpanzee 325 (B), were tested for anti-HCV cellular response using direct ex vivo IFN-
ELISPOT assay. Autologous PBLs from time 0 (before challenge) were infected with recombinant HCV-C-NS3-vaccinia (filled column), HCV-NS3-NS5-
vaccinia (unfilled column), at an m.o.i. of 10:1 and used as stimulator cells. IHLs at 1, 6, and 12 months postchallenge were incubated with stimulator cells
at 37°C and 5% CO2. The numbers of direct ex vivo IFN--secreting cells (ISCs) were measured 18 h after in vitro stimulation. The numbers of HCV-specific
ISCs/106 cells were plotted after subtracting the background (parental vaccinia virus alone). The cutoff value of direct ex vivo ISCs (horizontal line) was
calculated as described under Materials and methods as approximately 185.5 ISCs/106. The data represent the average of two experiments.
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says were done to detect HCV-specific effector cells. Bor-
derline, but detectable, ex vivo IFN- cellular immune re-
sponses were observed after the low-dose challenges. These
may represent responses to aborted or low-level viral rep-
lication. Attempts to detect viral RNA from sera or liver
biopsies after 1–10 RNA () virions challenges using quan-
titative PCR were unsuccessful (data not shown). Despite
this failure, low viral hepatic multiplication could not be
excluded completely due to the small fragments of liver
tissue analyzed from the liver biopsies, as well as the low
frequency of infected hepatocytes in HCV, specifically in
low-dose infections (Gosalvez et al., 1998). Moreover, us-
ing the Genprobe TMA assay which is more sensitive (14
copies/ml) (Giachetti et al., 2002), we confirmed a low level
of viral replication after 1 RNA () molecule in chimp 325
(Fig. 1B). Higher doses of infection 100 RNA () virions
induced detectable viremia and seroconversion as well as ex
vivo IFN- cellular responses in both chimpanzees, but with
variable intensities; the responses were, in general, stronger
in chimpanzee 251 than in chimpanzee 325. In expanding
the HCV-specific memory cells in vitro, HCV-specific
IFN- memory cells could be detected in both chimpanzees
with a range of 1500–2500 ISCs/106 cells even after chal-
lenge with low doses, 1–10 RNA () molecules. The level
of HCV-specific memory T cells did not increase after
challenge with 100 RNA () molecules. Remarkably, on
expanding the T cells in vitro using target cells infected with
ALVAC-HCV construct, the number of ISCs in response to
vector alone (background) was still higher than that without
expansion (148  360 and 78.7  54 ISCs/106 cells, re-
spectively). The reason for this increase in the background
is not clear, but it may represent an anamnestic response to
cross-reactive pox viruses or cross-reactive antigens (Brehm
et al., 2002; Kim et al., 2002; Welsh and Selin, 2002).
However, memory-specific HCV responses were still sig-
nificantly higher than the background with a cutoff value of
870.3 ISCs/106 cells. We also noticed that the numbers of
ISCs in expanded in vitro ELISPOT assay is not always in
agreement with that of ex vivo ELISPOT assay, probably
because they measured two different subpopulations of Ag-
specific T cells, namely memory and effector T cells, re-
spectively. Besides, the numbers of memory Ag-specific T
cells are influenced by the in vitro condition for expansion.
On dissecting the fine specificity of the immune response
to HCV antigens using pools (10 peptides) of NS3 10-mer
overlapping peptides, detectable levels of the IFN- re-
sponses to some of the pool peptides were mainly observed
in chimpanzee 251 prechallenge and postchallenges with 1,
10, and 100 RNA () virions. It is clear that chimpanzee
251 had a low-level preexisting immune response to cross-
reacting antigens to NS3 that is absent in chimpanzee 325.
The importance of the preexisting cross-reactive cellular
immune response in the outcome of infection has been
suggested by others (Brehm et al., 2002; Kim et al., 2002;
Wedemeyer et al., 2001; Welsh and Selin, 2002). Consistent
with the generalized weak response in chimpanzee 325, the
level of the IFN- responses to the pool of NS3 peptides
were very limited or absent even after challenges with 100
RNA () virions.
A discrepancy between the numbers of ISCs generated
by vaccinia-NS3 and NS3 peptides is observed. The reasons
for this discrepancy are not clear but comparison between
the two assays might be difficult for the following reasons:
(1) by using vaccinia-NS3, the target cells have to process
the NS3 before presenting to T cells. Besides, there is a
possible competition among NS3, vaccinia and endogenous
epitopes to MHC class I binding. In the case of ELISPOT
assay using overlapping NS3 peptides, the peptides bind
MHC class 1 without processing and without competition
with vaccinia peptides. (2) Stimulation with overlapping
peptides may underestimate the number of epitopes recog-
nized because they were 10-mer overlapping with offset of
2 Amino Acids (AA). Theoretically, they may represent
only 50% of the possible recognizable epitopes. (3) We
have used 10-mer peptide, which has been suggested as the
average optimum length of class I restricted peptides (range
from 8–13 AA), but this size may or may not be the
optimum length for the dominant NS3 peptides. (4) Due to
limitation of the available cells, peptides were used at one
concentration (4 M), which represents the response to
moderate affinity peptides. Therefore, we could underesti-
mate low avidity responses. Additionally, peptides were
used as pools of 10. Some peptides in the pool may act as
antagonists to the dominant epitopes without actual stimu-
lation of T cells and may lead to underestimation of the
responses.
Since measuring the immune response in PBMCs may
not reflect the local immune responses in the liver, we
monitored the HCV-specific immune response in IHLs. Due
to the low number of cells isolated from liver biopsies,
functional analysis of IHLs was limited. Detectable levels of
HCV-specific IFN- responses were seen after 1 and 6
months postchallenge in chimpanzee 251. Nevertheless, no
HCV-specific IFN- responses were detected after rechal-
lenge with 100 RNA, unlike those detected in the PBMCs.
The reasons for this are not clear but this may reflect the low
yield of IHLs with few HCV-specific lymphocytes in the
liver biopsies. Similar to cellular responses in peripheral
blood mononuclear cells (PBMCs) the IHL responses of
chimpanzee 325, in comparison to chimpanzee 251, were
absent or weak, even after challenge with 100 RNA ()
virions.
When proliferation to either HCV antigens or HCV pep-
tides (data not shown) was evaluated using 3H-thymidine
uptake, no significant proliferation (stimulation index, S.I.,
 3) was observed at all time points in both chimpanzees
except at one point: 6–8 weeks after challenge with 100
RNA () molecules in chimpanzee 251. Viability of the
frozen PBMCs was not the reason for the weak proliferation
observed, since stimulation index in response to PHA was
50 in all time points tested (data not shown), but weak
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responses to HCV Ags have been reported by others (Lauer
et al., 2002; Rico et al., 2002; Valdez et al., 2000).
One of the striking observations made from this study
was that chimpanzee 251 had preexisting cross-reacting
cellular immune responses to NS3 peptides of HCV. This
chimpanzee cleared the virus more rapidly after rechallenge
with 100 RNA () virions of HCV in comparison to chim-
panzee 325 that had no preexisting immune responses. It is
clear from our data that the outcome of infection as well as
the duration required for viral clearance are directly related
to the level of the immune responses induced by viral
challenge. For example, chimpanzee 251, who had strong
effector HCV-specific immune response, cleared the virus
within 12 weeks. By contrast, chimpanzee 325, who had
weaker immune responses, failed to clear the virus. How-
ever, the number of IFN--secreting memory-specific HCV
responses were in general lower in chimpanzee 325 by
comparison to chimpanzee 251. To address the possibility
of a qualitative difference in the HCV-specific memory T
cells, secreted IL-4 and TNF-alpha cytokines were mea-
sured. Quantitative analysis of IL-4 levels in the supernatant
of HCV-stimulated in vitro expanded PBLs showed no
differences (data not shown). However, a significant in-
crease (P  0.01) in the level of TNF- secretion by
memory T cells of chimpanzee 251 in comparison to chim-
panzee 325 has been observed after challenge with 10 and
100 RNA () molecules, as shown in Fig. 4A and B. The
role of TNF- in the outcome of HCV infection has been
suggested by other studies (Ando et al., 1997; Gruener et al.,
2001; Kakumu et al., 1997; Shata et al., 2002; Zhu et al.,
1998).
Three important conclusions can be drawn from this
study.
First, low doses of HCV infection can induce cellular
immune responses without persistently detectable viremia
or seroconversion. This conclusion is supported by the fol-
lowing data:
1. Memory HCV-specific T cells were established after
challenge with 1–10 RNA () molecules in both
chimpanzees and did not increase significantly after
rechallenge with higher doses.
2. Induction of effector HCV-specific IFN--secreting
cells in chimpanzees 251 after challenge with 1 and
10 RNA () molecules. The weak cellular immune
response in chimpanzee 325, even after challenge
with 100 RNA () molecules, may reflect an inher-
ited weakness in response to HCV.
3. Significant induction of HCV-specific ISCs in IHLs in
chimpanzee 251 even after challenge with 1 RNA ()
molecule. Chimpanzee 325 failed to induce signifi-
cant numbers of HCV-specific ISCs in IHLs even
after challenge with 100 RNA () molecules and
subsequently established viremia.
4. Borderline boosting of antibody responses was seen
in both chimpanzees after challenge with 10 RNA ()
molecules.
5. By using the more sensitive Genprobe TMA assay,
we were able to detect HCV RNA 4 weeks after
challenge with 1 RNA () molecule in chimpanzee
325. The failure to detect HCV RNA after low-dose
challenges in chimpanzee 251 may reflect the low
level of replication in this chimpanzee, the fluctuation
of the viremia level, as well as the small sample sizes.
The presence of preexisting NS3-specific ISCs in chim-
panzee 251 upon peptide stimulation is of great interest and
may reflect cross-reactive antigens (Brehm et al., 2002) or
previous unrecognized exposure to HCV. Attempts to iden-
tify strong HCV-specific memory T cells in chimp 251
prechallenge were not successful (data not shown). There-
fore, we are more inclined toward cross-reactive antigens as
an explanation for the presence of a preexisting cellular
immune response in this particular chimpanzee.
The second conclusion from out study is the correlation
between the outcome of HCV infection and the level of
induced cellular immune responses in the host. This is
supported by the fact that chimpanzee 251, which resolved
the infection, had early stronger cellular immune response
in comparison to chimpanzee 325, which became chroni-
cally infected with a low set point of viral load. However,
these immune responses failed to induce sterile immunity
against a challenge  100 RNA () molecules, although
they lowered the duration of viremia, and in chimpanzee
251, ultimately resulted in clearance of the infection.
The third conclusion from our study is the probable lack
of a role of anti-HCV in controlling viral replication. As
shown in Fig. 1, chimpanzee 325 had 1–2 log higher level
of anti-HCV in comparison to chimpanzee 251; however,
this chimpanzee failed to control viral replication and de-
veloped chronic HCV infection. It is interesting to notice
that the drop in viral load in chimpanzee 251 is associated
with an increase in the anti-HCV. It is not clear if these
antibodies have a role in the control of viral replication in
this chimpanzee and if there is a quality difference between
the anti-HCV in chimpanzee 251 and chimpanzee 325.
Materials and methods
Chimpanzees
Chimpanzees (Pan troglodytes verus) were housed in the
New York Blood Center’s primate laboratory, Vilab II, at
the Liberian Institute for Biomedical Research (LIBR) in
Robertsfield, Liberia. To titrate infectivity, two chimpan-
zees, 251 and 325, were experimentally infected sequen-
tially with HCV genotype 1b at different doses [1, 10, and
100 RNA () molecules]. Serum samples, and cryopre-
served PBMCs were taken at 1- to 4-week intervals up to 2
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years after challenge with HCV. Liver biopsies were taken
at 4-week intervals. Intrahepatic lymphocytes were pre-
pared from the liver biopsies as described below and cryo-
preserved in liquid N2 until analyzed. Serum samples were
frozen and stored at 70°C until examined.
Quantitation of HCV RNA
HCV RNA was quantitated using real-time PCR assay
with molecular beacon technology using a Perkin–Elmer
model 7700, as previously described (Lai et al., 1994a; Lee
and Prince, 2001; Takeuchi et al., 1999) with modifications.
Briefly, RNA was extracted from plasma, or lysate of liver
biopsies using Qiagen HCV RNA kits. PCR and cDNA
mixtures were set up with a Beckman Biomek 2000 pipet-
ting station in a laminar flow hood in a room dedicated to
PCR setup. This permits quantitation of both strong and
weak specimens by comparison with a standard curve de-
rived from serial dilutions of synthetic HCV RNA as per-
formed in this study; the method was sensitive to approxi-
mately 100 RNA molecules/ml using a synthetic RNA
standard and gives linear results between 102.5 and 107
RNA molecules/ml. This methodology has two major ad-
vantages: the ability to quantitate strong and weak speci-
mens from a single dilution, and the fact that the amplified
samples are not used for other assays, gel, or ELISA, which
can serve as a source for contamination. Quality control is
performed routinely by including 4–10 HCV negative con-
trol sera, and 2–4 positive sera, during each PCR run, as
external negative and positive controls, respectively, to
monitor the extraction and amplification efficiencies. As-
says in which positive control quantities are outside of the
mean  2 SD for all assays run (QA curve) are discarded.
Qualitative detection of HCV RNA
Transcription-mediated amplification was done as de-
scribed (Giachetti et al., 2002; Linnen et al., 2002). The
specificity of the TMA-driven assay is 99.5% in both
normal specimens and plasma containing potentially inter-
fering substances or other blood-borne pathogens. The sen-
sitivity of the assay is 14 copies/ml at 50% detection.
Titrating the infective doses of HCV
Chimpanzee 317 was infected with HCV strain 1b (BK)
at a dose of 10 CID50 and became chronically infected.
HCV viral load in the acute phase plasma (4 weeks post-
inoculation) was quantitatively measured using PCR as de-
scribed above. This plasma was found to have viral load of
106.32 copies/ml. The plasma was diluted to obtain different
concentrations of viral RNA molecules. Chimpanzees 251
and 325 were challenged intravenously initially with 1 ml of
plasma from chimpanzee 317 diluted to contain approxi-
mately 1 RNA () molecule/ml. After 6 months, both
chimpanzees were rechallenged with 1 ml of the diluted
plasma containing approximately 10 RNA () molecules.
After another 6 months, they were rechallenged again with
1 ml of the diluted plasma containing approximately 100
RNA () molecules. Between each challenge, sera and
PBMCs were collected at biweekly intervals, and liver bi-
opsies were obtained monthly.
HCV ELISA
Quantitative measurement of anti-HCV antibody re-
sponse was performed using Ortho HCV 3.0 ELISA test
system (Ortho Diagnostic System, Rariton, NJ), and serial
dilution of chimpanzee sera, and positive control sera was
performed according to the manufacturer’s instructions with
some modification. Briefly, dilution of positive control sera
with well-defined quantities of anti-HCV antibodies and
dilutions of chimpanzee sera were run simultaneously in the
Ortho HCV 3.0 ELISA test system. The level of anti-HCV
antibodies in the chimpanzee sera was expressed as units in
comparison to the positive control serum. One unit of pos-
itive control serum is equivalent to the dilution at 50%
binding. The results were expressed as units/ml.
Isolation and propagation of peripheral blood
lymphocytes
PBMCs drawn at different intervals after infection were
purified by Ficoll–Hypaque and then cryopreserved at 1°C/
min in the presence of 20% autologous serum and 10%
dimethyl sulfoxide (DMSO). Before performing any assay,
PBLs were thawed, washed three times, and counted for
functional analysis. The effect of freezing and thawing is an
issue of considerable importance. Therefore freshly isolated
and freeze/thawed PBLs were tested in parallel to establish
the effects of cryopreservation. The tested antigens induced
a comparable number of spots in ELISPOT assays with both
frozen as well as fresh PBLs (data not shown).
Isolation of liver infiltrating lymphocytes
The peripheral blood compartment may not be suffi-
ciently representative of the immune response in the in-
fected animals, since HCV-specific T cells may be prefer-
entially concentrated in HCV-infected liver. Therefore,
functional analysis of the intrahepatic lymphocytes was
done after challenge with HCV in parallel with the PBLs.
One problem of IHL analysis is the low yield of the liver
biopsy (approximately 2–5  105 cells/1–2 cm of liver
biopsy). Therefore, direct IFN- ELISPOT assay was done
using only 1–3  104 cells/well. To isolate IHLs, the liver
specimens were cut into small pieces and then treated with
collagenase IV (Sigma, 0.5 mg/ml) and DNAse (Sigma, 100
g/ml) at 37°C for 20–30 min with continuous shaking.
Treated samples were passed through a 200-gauge stainless
mesh and then resuspended in 1 ml of RPMI 1640 medium.
The cells were mixed with 4 ml of 30% (W/V metrizamide
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in PBS) and centrifuged at 1500 g for 20 min at 4°C in
15–ml conical tubes. Cells at the metrizamide/PBS interface
were collected and washed twice with RPMI and then
counted (Kawarabayashi et al., 2000). IHLs were function-
ally examined using IFN- ELISPOT assay as described
below.
Synthetic HCV peptides
NS3 peptides
A panel of 312 overlapping peptides with a length of 10
amino acids and offset of two, derived from the NS3 region
of genotype 1b, according to its sequences (Takamizawa et
al., 1991), was synthesized (Mimotopes Pty Ltd., Clayton
Victoria, Australia) and pools of 10 successive overlapping
peptides were used to study recognition by HCV NS3-
specific IFN--secreting cells. Data were presented as the
number of ISCs in the presence of pool peptides (10 over-
lapping 10-mer peptides) after subtracting the cut-off value.
The cutoff value of ISCs was calculated for each experiment
as the average number of ISCs in response to a control
peptide  2 SD and range from 100 to 200 ISCs/106 cells.
Generation of poxvirus recombinants expressing HCV
proteins
Recombinant virus
Hepatitis C genes from HCV-H (genotype 1a) and
HCV-BK (genotype 1b) were inserted into two poxviruses;
ALVAC, the vaccine strain of canarypox (Perkus et al.,
1989), and the L variant of WR, a laboratory strain of
vaccinia virus (Panicali et al., 1981; Perkus et al., 1989).
Poxvirus recombinants were generated as previously de-
scribed (Perkus et al., 1989). For construction of poxvirus
recombinants expressing an internal segment of HCV (e.g.,
NS2 or NS3), the poxvirus promoter was immediately fol-
lowed by an initiation codon, which was added to the native
HCV cleavage site. To maximize gene expression, all oc-
currences of the T5NT poxvirus early transcription termi-
nation signal in the HCV sequences were mutagenized with-
out changing the encoding amino acid (Yuen and Moss,
1987). These constructs have been used successfully in our
laboratory to infect target cells for in vitro stimulation of
HCV-specific CD8 T cells in 51Cr-release assay (Cohard
et al., 1998) as well as in ELISPOT assay (Pancholi et al.,
2000; Prince and Shata, 2001; Shata et al., 2002).
IFN- ELISPOT assay
ELISPOT assay was done according to the manufacturer’s
instructions contained in the -IFN ELISPOT Kit
(MABTECH Cat. No. M34201-A, Sweden) with modifica-
tions. Briefly, 96-well nitrocellulose-bottomed Millititer
plates (Millipore, Bedford, MA) were coated with murine
anti-human IFN- mAb at concentration of 15 g/ml in
PBS and incubated at 4°C. After 24 h, the plates were
washed and blocked with 10% human AB serum (1 h at
37°C). For in vitro expanded ELISPOT assay, autologous
PBMCs from the chimpanzee before infection (defined as
time 0 PBMCs) were infected with recombinant ALVAC-
HCV, or control ALVAC at a multiplicity of infection
(m.o.i.) 10:1, and used as stimulator cells. PBMCs at dif-
ferent time points postchallenge were incubated with the
stimulator cells at E:T ratio of 10:1 as described (Cohard et
al., 1998; Wong et al., 2001). Ten units/ml of recombinant
IL-2 (R&D Systems, Minneapolis, MN, USA) were added
on the third day. On day 6, expanded T cells were washed
three times and counted. To estimate the number of HCV-
specific interferon- secreting cells, in vitro expanded or ex
vivo unexpanded PBMCs were added at different concen-
trations (104–105 cells/well) in 100 l volume of complete
medium (RPMI-1640 containing 10% AB serum). The
stimulator cells, autologous PBMCs at time 0, infected with
either recombinant vaccinia-HCV or parental vaccinia at
m.o.i. of 10:1, were added at a concentration of 105 cells/
well in 100 l volume of complete medium. In the case of
peptide stimulation, the unexpanded ex vivo PBMCs were
pulsed with the test peptides at a concentration of 4 nM as
described (Shata et al., 2002; Tobery et al., 2001). After
18-h incubation at 37°C, the plates were washed five times
with washing buffer, PBS containing 0.5% (v/v) Tween 20
(Sigma, St. Louis, MO), using an ELISPOT plate washer
(Millipore). Biotinylated anti-human IFN- mAb (clone
4S.B3) at a concentration of 1 g/ml in blocking buffer,
PBS containing 0.5% (v/v) Tween 20 and 1% (w/v) bovine
serum albumin (Sigma), was added, and the plates were
incubated at room temperature for 2 h. Plates were then
again washed five times, and streptavidin-HRP (1:1000) in
blocking buffer was added and incubated at room temper-
ature for 2 h, followed by washing five times with washing
buffer and the addition of substrate 3-amino-9-ethyl carba-
zole (AEC) reagent in substrate buffer (Sigma). After de-
veloping the spots for 10–15 min, the plates were washed
with distilled water and air-dried. The number of spots was
enumerated using a computerized-assisted ELISPOT image
analyzer (Zeiss System, Axioplan 2 imaging), and KS
ELISPOT 4.2 program (Zeiss), designed to detect spots
using predetermined criteria based on size, shape, and col-
orimetric density. Analysis of the data was calculated from
the equation:
Ag-specific ISCs/106 cells No. of ISCs
in response to Ag/106 cells No. of ISCs
in the presence of media alone/106 cells.
HCV-specific ISCs were plotted after subtracting the num-
ber of ISCs induced by parental vaccinia. The average
numbers of direct ex vivo, or expanded ISCs induced by
parental vaccinia calculated from 16 experiments, were 78.7
 54 and 148  360 ISCs/106, respectively. The cutoff
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level of ISCs is calculated as the average number of ISCs in
the presence of parental vaccinia  2 SD and were 185.5
and 870.3 ISCs/106 cells for the direct ex vivo and expanded
ISCs, respectively. To eliminate samples with poor viabil-
ity, those having PHA responses 2500 ISCs/106 cells,
equivalent to the mean  2 SD of all the samples tested in
18 experiments, were excluded from analysis. The average
numbers of (ISCs)/106 cells, after PHA stimulation, in three
uninfected chimpanzees and six chronically HCV-infected
chimpanzees, were 3783.3  398.2 and 5148.1  1241,
respectively.
T cell proliferation (3H-thymidine uptake)
PBMCs, prepared as described above, were added at a
concentration of 105 cells per well in 96-well round-bottom
tissue culture plate in a volume of 100 l. The medium
consisted of RPMI-1640 with 2 mM glutamine, antibiotics,
5 mM HEPES buffer, and either 10% human AB serum or
chimpanzee serum. Cultures were incubated with pooled
HCV antigens (c22-3, rNS3, c200, HCV-NS5) kindly pro-
vided by Dr. Michael Houghton (Chiron, Emeryville, CA)
at 1 g/ml for each individual protein, as described (Rosen
et al., 1999; Tsai et al., 1997), or with PHA (5 g/ml)
(Sigma). The cells were incubated at 37°C in humidified 5%
CO2. On the sixth day 50 l of fresh medium containing 1
Ci of 3H-thymidine was added for each well. After 18 h,
the cells were harvested using a Skatron Combi cell har-
vester (Molecular Devices Corp., CA), and the 3H-thymi-
dine incorporation was counted using a Microbeta Plus
1450 Liquid Scintillation Counter (Perkin–Elmer Life Sci-
ence, MA). Stimulation index was calculated from the equa-
tion:
Stimulation index (S.I.)

CPM in the presence of pooled HCV proteins
CPM in the presence of medium alone .
To eliminate samples with poor cell viability, data were
excluded from the analysis if the stimulation index after
PHA stimulation was less than 10.
Cytokine measurement in the supernatant of HCV-specific
memory cells
The levels of cytokines (IL-4 and TNF-) in the super-
natant from ex vivo expanded C-NS3 specific memory T
cells, after in vitro restimulation for 24 h with Vaccinia-C-
NS3-infected PBLs (at time 0), were measured using Hu-
man IL-4 OptEIA kit (BD Biosciences, San Jose, CA, Cat.
No. 2678KK) and human-TNF- OptEIA kit (B.D. Bio-
sciences, Cat. No. 2600KK), according to the manufacturer’s
instructions. The cutoff level was calculated as the level of
cytokine in the presence of parental vaccinia vector alone
 2 SD.
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